Key facts
- GT Medical Technologies’s last known valuation is $215.3M (Jun 2025).
- It has raised $161.5M across 6 recorded rounds; the latest was Later Stage VC ($53.3M) in Dec 2024.
- Notable investors include MedTech Innovator, Gilde Healthcare, Arizona Commerce Authority, FemHealth Ventures, Flinn Foundation — 18 tracked in total.
- GT Medical Technologies has filed 8 Form Ds with the SEC since 2017, most recently Jun 2025 ($53.3M sold to 37 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for GT Medical Technologies
Funding rounds
6 roundsAbout GT Medical Technologies
Developer of a medical therapeutic device designed to overcome the limitations of current treatments by placing it after the tumor removal. The company's device features a bioresorbable, conformable, collagen tile and a uniform radiation source that utilizes advanced brachytherapy techniques, minimizing radiation exposure to healthy tissue, reducing side effects, and decreasing treatment burden, enabling medical practitioners to prevent disease progression and improving the quality of life for their patients.
- Sector
- Healthcare
- HQ
- Tempe, AZ, United States
- Founded
- 2017
- Employees
- 100
- Website
- gammatile.com/
- Ownership
- Privately Held (backing)
GT Medical Technologies doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in GT Medical Technologies shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on GT Medical Technologies in its N-PORT filings yet. We sweep new filings monthly.